Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against